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Weight-loss after bariatric surgery improves insulin sensitivity, but the underlying molecular
mechanism is not clear. To ascertain the effect of bariatric surgery on insulin signalling, we
examined glucose disposal and Akt activation in morbidly obese volunteers before and after
Roux-en-Y gastric bypass surgery (RYGB), and compared this to lean volunteers.
Materials and Methods
The hyperinsulinaemic euglycaemic clamp, at five infusion rates, was used to determine
glucose disposal rates (GDR) in eight morbidly obese (body mass index, BMI=47.3±2.2
kg/m2) patients, before and after RYGB, and in eight lean volunteers (BMI=20.7±0.7 kg/m2).
Biopsies of brachioradialis muscle, taken at fasting and insulin concentrations that induced
half-maximal (GDR50) and maximal (GDR100) GDR in each subject, were used to examine
the phosphorylation of Akt-Thr308, Akt-473, and pras40, in vivo biomarkers for Akt activity.
Results
Pre-operatively, insulin-stimulated GDR was lower in the obese compared to the lean indi-
viduals (P<0.001). Weight-loss of 29.9±4 kg after surgery significantly improved GDR50
(P=0.004) but not GDR100 (P=0.3). These subjects still remained significantly more insulin
resistant than the lean individuals (p<0.001). Weight loss increased insulin-stimulated skel-
etal muscle Akt-Thr308 and Akt-Ser473 phosphorylation, P=0.02 and P=0.03 respectively
(MANCOVA), and Akt activity towards the substrate PRAS40 (P=0.003, MANCOVA), and
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in contrast to GDR, were fully normalised after the surgery (obese vs lean, P=0.6, P=0.35,
P=0.46, respectively).
Conclusions
Our data show that although Akt activity substantially improved after surgery, it did not lead
to a full restoration of insulin-stimulated glucose disposal. This suggests that a major defect
downstream of, or parallel to, Akt signalling remains after significant weight-loss.
Introduction
Weight gain is a major risk factor for the development of Type 2 Diabetes (T2DM) and the
relative risk increases dramatically with even a small increase in weight [1]. Weight gain is
thought to have its effect by reducing the effectiveness of insulin action. Insulin-stimulated glu-
cose uptake in skeletal muscle and adipocytes tissues is impaired in obesity and T2DM, causing
peripheral insulin resistance (IR). Furthermore, insulin resistant obese individuals have re-
duced insulin sensitivity and maximal insulin-stimulated glucose uptake when compared to
lean individuals [2, 3].
The molecular basis of IR is poorly understood. Insulin increases glucose uptake into muscle
and adipose tissue by promoting the translocation of GLUT4 (glucose transporter isoform 4)
from the cell interior to the plasma membrane [4, 5]. The fact that GLUT4 expression is not re-
duced in those with insulin resistance, such as in the obese and T2DM [6, 7], suggests that the
major underlying defects in this condition are likely to lie in the insulin signal transduction
pathways and/or the translocation of GLUT4 to the plasma membrane in skeletal muscle. Re-
duction in insulin stimulated phosphorylation of the insulin receptor and IRS-1, and reduced
activity of PI3-kinase in T2DM suggest that defective insulin signalling may be, at least in part,
responsible for insulin resistance [8].
Adipose tissue secretes a number of endocrine and inflammatory mediators, including free
fatty acid (FFA) and adipokines (e.g. tumour necrosis factor α, Adiponectin, Leptin and Resis-
tin) that influence insulin sensitivity and glucose homeostasis. Elevated FFA secretion associat-
ed with fat mass expansion is widely believed to play an important part in insulin resistance
with it affecting the phosphorylation of IRS-1 and pathways that link into this [9, 10].
Akt is an insulin-stimulated serine/threonine-specific protein kinase that is well established
as a critical component of the signalling mechanism used by insulin to stimulate glucose uptake
[11–14]. A reduced ability of insulin to stimulate Akt in skeletal muscle has been observed in
several studies of human IR [15–18], although others have disputed this [19–23]. This discrep-
ancy could be due to the different experimental approaches used in these studies, including the
use of different insulin infusion rates during hyperinsulinaemic euglycaemic clamps (HEC) or
differences in the degree of obesity or glycaemic status of the subjects.
Studies that employ a single insulin concentration for both the control and affected group
(i.e. obese, T2DM), either at the lower physiological or supra-physiological ends [15], provide
limited insight into dynamic molecular activity. A given insulin concentration may fall outside
the effective insulin range for one group and thus fail to provoke an observable physiological
response, or only provoke a partial response, and thus lead to misleading results. Construction
of a detailed insulin dose response curve specific to an individual is important in allowing dy-
namic assessment of the insulin signalling pathway and allows for better comparison between
individuals [2].
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Bariatric surgery can bring about substantial and sustainable weight loss in patients with
morbid obesity, with patients losing 40–60% of their excess weight and maintaining this
weight-loss for more than 10 years [24]. Despite this considerable weight-loss in patients with
T2DM, studies have shown that although diabetes control is improved in the majority, a ‘cure’
(confirmed against 2009 ADA agreed criteria for remission [25]) is only seen in 40–50% of pa-
tients undergoing bariatric surgery [26, 27] and, of these, 10% see a recurrence in their diabetes
each year [28]. One possible explanation for this is that insulin sensitivity is only partially nor-
malised through augmentation of Akt activity in response to surgery.
In an attempt to clarify the role Akt plays in modulating insulin sensitivity after significant
weight-loss through bariatric surgery, we carried out a detailed examination of the correlation
between insulin-stimulated glucose disposal and Akt signalling in eight morbidly obese insulin
resistant volunteers before and after a Roux-en-Y gastric bypass (RYGB). For each volunteer,
we constructed a detailed insulin dose response curve for glucose disposal rates (GDR) calcu-
lated from HEC using 5 different insulin infusion rates. This was used to estimate the insulin
concentrations required to induce half-maximal (GDR50) and maximal (GDR100) glucose dis-
posal. In a second shorter clamp, forearm muscle biopsies were taken at three insulin infusion
rates (fasting, GDR50 and GDR100), which allowed insulin signalling to be examined across the
full physiological range for each individual. To study insulin signalling, we measured the state
of phosphorylation of Akt on both Thr308 and Ser473, sites which play a role in the regulation
of kinase activity and thus glucose uptake [29, 30]. We also assessed phosphorylation of the
Akt substrate PRAS40, which we have shown previously to be an in vivo biomarker of Akt ac-
tivity [30, 31]. Glucose disposal and insulin signalling were compared to eight lean volunteers.
Materials and Methods
Materials
Anti-phospho-Akt (Thr308), anti-phospho-Akt (Ser473) and anti-phospho-PRAS40 (T246)
antibodies were purchased from Cell Signaling Technology (Danvers, MA, US) and an anti-
total Akt2 antibody from Upstate (Hampshire, UK). Unless otherwise stated all other materials
were purchased from Sigma Aldrich (Dorset, UK). Serum glucose samples were run using
Abbot Architect c Systems reagent kit, with a limit of detection of 0.139mmol/L and an assay
precision of<5% total CV. Serum insulin samples were run using Abbot Architect chemilumi-
nescent microparticle immunoassay (CIMA), with a limit of detection of 1 μU/ml and an assay
precision of<7% total CV.
Research volunteers
Eight lean and eight obese white Caucasian volunteers participated in this study. The lean vol-
unteers consisted of 4 females and 4 males, mean age 27.5±3.1 (mean ± SEM) years, BMI of
20.7±0.7 kg/m2 and were on no medication (Table 1). The obese volunteers consisted of 6 fe-
males and 2 males, mean age of 47.9±3.5 years and BMI of 47.3±2.2 kg/m2. Four of these obese
volunteers had T2DM treated with oral medication (Table 2).
Study design
All participants took part in a screening visit (visit 1), a long HEC (visit 2), a short HEC (visit
3) and a review visit (visit 4). For the obese participants, visits 2–4 were repeated at least 4
months (mean 6.8±1.2) post RYGB surgery. The RYGB procedures were performed laparosco-
pically by an experienced surgeon using an omega loop technique creating a 15 to 20 mL gastric
pouch with a retrocolic antegastric Roux limb of 100 cm.
Bariatric Surgery and Insulin Resistance
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At visit 1 a medical history was taken and a physical examination performed. Blood samples
were taken for full blood count, clotting screen, urea and electrolytes, liver function, and fasting
free fatty acids (FFA) (measured by the colourmetrix method, Randox Laboratories Limited, UK).
Ethics
Ethical approval was granted by South West 1 Research Ethics Committee and the study was
sponsored by the University of Bristol, UK. Informed written consent was obtained from all
the participants. All participants were adults older than 18 years. The study was carried out in
accordance with the principles of the Declaration of Helsinki as revised in 2000.
Long hyperinsulinaemic euglycaemic clamp for insulin dose response
curve
Subjects attended at 8am having fasted from 11pm the night before and remained fasted
throughout the test. All anti-diabetic medications were stopped for at least 24 hours before the
clamp study. A cannula was placed in an antecubital vein for infusion of insulin (Actrapid,
Novo Nordisk, UK) and glucose solution (5%, 10% or 20%; Baxter Pharmaceuticals, UK) and a
Table 1. Clinical characteristics and biochemical observations for lean volunteers.
Lean Sex Age (year) Weight (kg) Height (cm) BMI (kg/m2) Diabetes Fasting BG (mmol/L)
1 m 28 65 188 18.4 no 4.6
2 f 29 54 160 21.1 no 5
3 f 47 53 165 19.5 no 4.9
4 m 25 65 181 19.8 no 5.1
5 f 22 62 178 18.9 no 5.1
6 m 21 75 189 21 no 5.2
7 m 29 86 186 24.9 no 4.7
8 f 19 60 165 22 no 4.1
mean±SEM 27.5±3.1 65.0±3.9 176.5±4.1 20.7±0.7 4.8±0.1
doi:10.1371/journal.pone.0120084.t001
Table 2. Clinical characteristics and biochemical observations for obese volunteers before and after weight loss surgery.




HbA1c (%) Fasting free fatty acids
(μmol/L)
Pre Post Pre Post Pre Post Pre Post Pre Post
1 F 37 Yes 54.8 33.5 SU, TZD None 12.3 5.2 7.5 5.9 528 470
2 M 45 Yes 50.3 38.3 Met, TZD None 9.6 5.4 7.9 5.4 763 1143
3 M 57 Yes 37.4 29.5 Met, SU None 11.9 6.2 8.5 7.4 978 489
4 F 53 Yes 54.5 46.7 Met, SU None 8.6 6.3 7.8 7.1 861 866
5 F 56 No 44.4 36.2 None None 4.6 4.1 771 838
6 F 56 No 48.2 41.1 None None 6.1 5.1 923 1005
7 F 49 No 41.5 32.9 None None 6 4 1500 604
8 F 30 No 47.4 35.6 None None 3.6 4.7 845 653
Mean ± SEM 47.9±3.5 47.3±2.2 37±1.9* 7.8±1.2 5.1±0.3* 7.9±0.2 6.5±0.5* 896.1±98.6 758.5±86.3
Abbreviations for medications as follows; sulphonylureas (SU), metformin (Met) and rosiglitazone (TZD). HbA1c was only measured in patients
with diabetes.
* = significant difference pre vs post with p<0.05
doi:10.1371/journal.pone.0120084.t002
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second cannula placed retrogradely in a contralateral dorsal hand vein, the hand being kept in
a heat pad for arterialised blood sampling.
Insulin was infused at five different rates, 0.2, 0.5, 1, 2 and 5 mU/kg/min and this was in-
creased in a stepwise fashion every 2 hours [32]. A priming bolus dose of insulin was given at
the beginning of each increase and blood glucose (BG) levels were monitored every 5 minutes
using a glucose-monitoring device (One-Touch Ultra, Life Scan Limited, UK). Using this infor-
mation, the rate of glucose infusion was adjusted to maintain BG at 5mmol/L. In addition to
frequent bedside glucose monitoring, samples were obtained for laboratory serum blood glu-
cose and insulin level [33].
Blood was immediately centrifuged, and the plasma was frozen and stored at −80°C until
analysis. Steady-state glucose uptake was achieved at 90 minutes during each of the 2-hour in-
fusion periods. GDR were calculated from infusion rates of glucose in the final 30 min of each
rate of insulin. Insulin response curves were constructed using these data and subsequently
used to determine the insulin infusion rates required to induce half-maximal (GDR50) and
maximal (GDR100) glucose disposal for each individual.
Short hyperinsulinaemic euglycaemic clamp
Participants re-attended for a short HEC within 6 weeks of the long clamp. Again they attended
at 8am having fasted from 11pm the night before and remained fasted throughout the test. All
anti-diabetic medications were stopped for at least 24 hours before the clamp study. Similar
procedures were followed as described for the long hyperinsulinaemic euglycaemic clamp.
In brief, two cannulas were used: one was placed in the antecubital vein for infusion of insu-
lin and glucose solution and the other retrograde in the cannula in a contralateral dorsal hand
for blood sampling.
Insulin was infused at two different rates, the infusion rate predicted from the long clamp to
achieve GDR50 and the infusion rate predicted to achieve GDR100. A priming bolus dose of in-
sulin was given at the beginning of each increase and blood glucose (BG) levels were monitored
every 5 minutes using a glucose-monitoring device (One-Touch Ultra, Life Scan Limited, UK).
Using this information, the rate of glucose infusion was adjusted to maintain BG at 5mmol/
L. In addition to frequent bedside glucose monitoring, samples were obtained for laboratory
serum blood glucose and insulin level at the start and end of each infusion rate to ensure the ex-
pected insulin concentration had been obtained.
Muscle biopsies were taken at baseline, 45 minutes after the initiation of an insulin infusion
rate that was predicted from the long clamp to achieve GDR50, and then again 45 minutes after
the start of an insulin. Biopsies were briefly washed in ice-cold phosphate-buffered saline to
remove residual blood and then immediately frozen in liquid nitrogen and stored at -80C
until analysis.
An interval of 45 minutes was chosen as the original hyperinsulaemic clamp study by
Defronzo RA [33] demonstrated that insulin concentrations reach a steady state by 20 minutes.
In addition Middelbeek et al have shown that Akt Thr308 and AS160 phosphorylation was
similar in biopsies taken at 30 minutes and 180 minutes into a hyperinsulaemic clamp study in
lean and obese patients with and without diabetes [34].
Muscle biopsies
Biopsies were carried out under local anaesthesia (10ml Bupivacaine, 0.5%) from the radial
aspect of the non-dominant proximal forearm, which was chosen as it would allow us direct ac-
cess to muscle with the least risk of infection in this particular group of patients. After an incision
and blunt dissection, a 10 cm stretch of brachioradialis muscle was exposed for biopsy. Three 4
Bariatric Surgery and Insulin Resistance
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mm punch biopsies (30–50 mg of protein) were obtained at the proximal (first biopsy), distal
(second biopsy) and middle (third biopsy) section of the exposed muscle with at least 5 cm be-
tween the biopsy sites. Between biopsies the wound was closed with steristrips and covered with
gauze. At the end of the procedure the wound was closed using 4/0 Vicryl and 5/0 Ethilon.
Tissue processing
Muscle biopsies were homogenised in 40 μl of ice-cold extraction buffer (50 mM Tris pH 7.5,
120 mMNaCl, 1% Nonidet P40, 40 mM β-glycerophosphate, 1 mM benzamidine, 1 mM
EDTA, 50 mMNaF, 10 mM Na4P2O7, 10 μg/ml pepstatin, 10 μg/ml antipain, 10 μg/ml leupep-
tin, 2 μMmicrocystin, 5 mM Na3VO4, 2 mM phenylmethylsulfonyl fluoride) per mg of wet
muscle using a Polytron homogenizer for a total of 1 minute. Tissue lysates were rotated for 45
minutes at 4°C before being cleared by centrifugation (16,000g for 15 minutes at 4°C). Protein
concentration was determined using a commercial kit (protein assay from Bio-Rad, Hemel
Hempstead, UK), and adjusted to 2 mg/ml with extraction buffer.
Western blotting
50 μg aliquots of muscle protein were solubilised with 4x Laemmli sample buffer and, proteins
were separated by SDS-PAGE using 4–12% gradient gels and transferred to polyvinylidene difluor-
ide membranes (Millipore, Hertfordshire, UK). Membranes were blocked using 7.5% (w/v) non-fat
dry milk in TBS-T (20 mMTris pH 7.6, 137 mMNaCl, 0.1% Tween-20) for 1 hour. Membranes
were washed, incubated with either anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), anti-
phospho-PRAS40 (T246), or anti-total Akt2 antibodies for 1 hour (all 1 μg/ml in TBS-T containing
5% w/v bovine serum albumin), before washing and incubating with the appropriate secondary an-
tibodies diluted in TBS-T for 1 hour. Immunoblots were visualised using an Enhanced ChemiLu-
minescence detection system (ECL; GE Healthcare, Buckinghamshire, UK), and quantified by
densitometry (Scion Image Software; Scion cooperation, Frederick, MD). Inter-blot comparison of
phosphorylation levels was possible due to the inclusion of a positive control (lysate from insulin-
stimulated rat adipocytes) on every SDS-PAGE gel to which other bands were normalised.
Statistics
All data are expressed as the mean ± standard error of the mean (SEM). Clinical data between
the obese and lean groups were compared using the unpaired t-test and between the obese pa-
tients before and after surgery using the paired t-test. When examining GDR, differences in
insulin sensitivity between lean and obese groups were tested using multivariate analysis of co-
variance (MANCOVA). In this dose-response model, the initial GDR measurement and the re-
peated measures of GDR at different insulin infusion rates were taken into account as well as
the pairing of subjects when comparing pre versus post operation GDR in the obese group.
Differences in trajectories of Akt-Ser473, Akt-Thr308 and PRAS40-T246 phosphorylation
as a function of plasma insulin concentration between lean and obese groups were compared
graphically and using the MANCOVA F-test. When comparing obese pre versus post opera-
tion Akt-Thr308, Akt-Ser473 and PRAS40-T246 phosphorylation, pairing of subjects was
taken into account.
Results
Comparison of insulin sensitivity in the lean and obese subjects
Fig 1 shows the glucose and insulin concentrations obtained from blood samples taken
during the long HEC. Although the obese volunteers (pre-surgery) started the long clamp
Bariatric Surgery and Insulin Resistance
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with a higher plasma glucose (7.8±1 vs 4.9±0.2 mmol/L, P = 0.007), glucose was subsequently
maintained close to 5 mmol/L in both groups at all insulin infusion rates (Fig 1A). Plasma insu-
lin concentrations were similar in each group at the start of the clamp but increased more in
the obese subjects relative to the lean subjects (P =<0.01, Fig 1B).
Fig 1. Glucose disposal rates in lean and obese volunteers before and after surgery. A comparison of
glucose concentration (panel A), insulin concentrations (panel B) and glucose disposal (panel C), between
lean (filled triangles) and obese volunteers before (open circles; pre-op) and after (filled squares; post-op)
surgery, measured during a 10 hour hyperinsulinaemic euglycaemic clamp. Insulin infusion rates of 0, 0.5, 1,
2 and 5 mU kg-1 min-1 were used. Data points represent the mean ± SEMwhere * represents P<0.05
determined by unpaired t tests, between lean and pre-op obese volunteers; + represents P<0.05 determined
by unpaired t tests between lean and post-op obese volunteers; # represents P<0.05 determined by paired t
tests between pre-op and post-op obese volunteers. Glucose disposal rates were different between lean and
obese volunteers (MANCOVA, P<0.001), and in obese volunteers before and after surgery (MANCOVA,
P<0.05).
doi:10.1371/journal.pone.0120084.g001
Bariatric Surgery and Insulin Resistance
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The insulin dose response curve for glucose disposal in obese volunteers (pre-surgery) is sig-
nificantly shifted down and to the right compared to lean subjects (Fig 1C). This is evidenced
by lower GDR at all insulin infusion rates examined and higher insulin infusion rate or plasma
insulin concentration required to induce GDR50 (MANCOVA P<0.001). This reduction could
be readily seen whether we plotted GDR against insulin infusion rate (Fig 1C) or against the
plasma insulin concentration achieved at each infusion rate in each subject (Fig 2A).
Phosphorylation of Akt on Thr308 (B) or Ser473 (C), and PRAS40 on T426 (D) were deter-
mined by western blotting for each volunteer and quantified by densitometry using an internal
standard. Data points represent the mean ± SEM of the phosphorylation score against the mean
insulin concentration seen at baseline, GDR50 and GDR100. Before surgery, Akt phosphorylation
on Thr308 across the dose response profile was reduced in the obese volunteers when compared
to the lean (Fig 2B; P = 0.06 using a MANCOVA F-test); Ser473 phosphorylation also showed a
tendency to a reduction (Fig 2C; P = 0.15). Weight loss increased skeletal muscle Akt phosphor-
ylation on both Thr308 and Ser473 (P = 0.020 and P = 0.027, respectively; MANCOVA F-test).
PRAS40 was reduced in the obese compared with lean volunteers across dose response profile
(P = 0.006, using MANCOVA F-test). After surgery, PRAS40 phosphorylation on T246 recov-
ered in the obese volunteer (P = 0.003, MANCOVA F-test), and was no longer significantly dif-
ferent from the lean controls (P = 0.46, respectively; MANCOVA F-test).
Glucose disposal rates were different between lean and obese volunteers (MANCOVA,
P<0.001), and in obese volunteers before and after surgery (MANCOVA, P<0.05). Phosphor-
ylation of Akt on Thr308 (C) and Ser473 (B) were compared between lean and obese volun-
teers (P = 0.06 and P = 0.15 respectively), and in obese volunteers before and after surgery
(P = 0.020 and P = 0.027 respectively). However, there were no statistical differences between
the lean and obese volunteers after surgery.
Comparison of insulin-stimulated Akt and PRAS40 phosphorylation
between lean and obese subjects
Insulin signalling in obese versus lean volunteers were compared. Before surgery, Akt phos-
phorylation on Thr308 across the dose response profile was reduced in the obese volunteers
when compared to the lean non-insulin resistant volunteers (Fig 2B; P = 0.06 using a MAN-
COVA F-test). Ser473 phosphorylation also showed a tendency to a reduction (Fig 2C;
P = 0.15). PRAS40 phosphorylation was also reduced in the obese compared with lean volun-
teers across the dose response profile (Fig 2D, p = 0.006, using a MANCOVA F-test).
Comparison of insulin sensitivity in obese subjects before and after
surgery
Surgery resulted in a mean weight-loss of 29.9±4.0 kg (135.2±7.1 vs 105.3±6.9 kg, P<0.001,
Table 2), with accompanied glycaemic improvement. In those volunteers with diabetes, reduc-
tions in fasting plasma glucose (7.8±1.2 vs 5.1±0.3mmol/L, P = 0.01) and HbA1c were observed
(7.9±0.2 vs 6.5±0.5%, P = 0.02), together with cessation of all diabetes medications (Table 2).
The plasma insulin concentrations attained were similar across all infusion rates, except
during the 0.5 and 5 mU/kg/min infusion rates where the insulin concentrations achieved were
lower post-operatively (42.7±4.5mIU/L vs 52.3±5.5 mIU/L, P = 0.03; and 765±96.2 mIU/L vs
925±121.6 mIU/L, P = 0.04; respectively, Fig 1B).
Weight loss resulted in a significant improvement in insulin-stimulated glucose disposal
(MANCOVA, P = 0.03, Figs 1C and 2A) with the response curve shifting to the left (i.e. less in-
sulin was required to induce a GDR50 response (73.3±12.8 post-surgery vs 131.3±25.7 mIU/L
pre-surgery, P<0.001), Fig 2A). Despite this improvement, the obese group still remained
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Fig 2. Summary of glucose disposal rates and insulin signalling in lean and obese volunteers, pre and
post weight loss surgery. A comparison of glucose disposal (panel A), phosphorylation of Akt on Thr308
(panel B), phosphorylation of Akt on Ser473 (panel C) and phosphorylation of PRAS40 on T426 (panel D)
between lean (filled triangles) and obese volunteers before (open circles; pre-op) and after (filled squares;
post-op) surgery. The glucose disposal was measured during a 10 hour hyperinsulinaemic euglycaemic
clamp with insulin infusion rates of 0.2, 0.5, 1, 2 and 5 mU kg-1 min-1. Data points represent the mean ± SEM
with the glucose disposal plotted against the mean insulin concentration achieved at each insulin
infusion rate.
doi:10.1371/journal.pone.0120084.g002
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more insulin resistant than the lean (i.e. obese patients required more insulin to induce a
GDR50 response than the lean (73.3±12.8 post-surgery vs 33.8±11.9 mIU/L lean, P = 0.012, Fig
2A); at an insulin infusion rate of 1 mU/kg/min, glucose disposal was 4.8±0.7 mg/kg/min in
obese volunteers post-surgery versus 10.8±0.6 mg/kg/min in the lean (P<0.001). Maximal
GDRs reached 7.3±0.6 mg/kg/min in the obese post-surgery versus 13.9±0.5 mg/kg/min in the
lean (P<0.001).
Comparison in insulin-stimulated Akt and PRAS40 phosphorylation in
obese subjects before and after surgery
As shown in Fig 2B and 2C, weight loss was accompanied by an increased skeletal muscle Akt
phosphorylation on both Thr308 and Ser473 (P = 0.020 and P = 0.027, respectively; MAN-
COVA F-test). PRAS40 phosphorylation on T246 also improved (P = 0.003, MANCOVA
F-test). After surgery insulin-stimulated Akt-Thr308 and Ser473 phosphorylation, as well as
PRAS40-Thr246 phosphorylation were not significantly different from the lean controls
(P = 0.6, P = 0.35 and P = 0.46, respectively; MANCOVA F-test). A representative experiment
is shown in Fig 3.
Discussion
This study aimed to explore the molecular basis underlying the impairment in insulin stimulated
glucose disposal observed in obesity. A comprehensive examination of Akt phosphorylation was
performed in skeletal muscle of lean and morbidly obese individuals at fasting and at higher
plasma insulin concentrations, corresponding to half maximal (GDR50) and maximal (GDR100)
levels of glucose disposal for each individual. Repeating these studies four months after the obese
participants underwent a Roux-en-Y gastric bypass, a procedure that led to significant weight
loss and cessation of requirement for diabetes medication, enabled us to look at the effect of
weight loss on Akt phosphorylation and activity, and glucose disposal rates in response to insu-
lin. We used lean controls as a benchmark for optimum insulin signalling and sensitivity.
Fig 3. Insulin signalling in obese volunteers, pre and post weight loss surgery.Obese volunteers (pre
and post-op) underwent a 3-hour euglycaemic hyperinsulinaemic clamp and muscle biopsies were taken at
fasting (0) and insulin infusion rates predicted to achieve half maximal (GDR50) and maximal (GDR100) rates
of glucose disposal. The extent of phosphorylation of Akt on Thr308, Ser473 and PRAS40 on T246 was
determined by western blotting. The results shown are from a single individual, but are representative of the
eight obese volunteers [see Materials and Methods].
doi:10.1371/journal.pone.0120084.g003
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As expected, when examining whole body glucose disposal, the morbidly obese individuals
were significantly less insulin sensitive than the lean volunteers. The insulin dose response
curve was shifted down and to the right. GDRs were lower at all insulin infusion rates exam-
ined (Figs 1C and 2A). RYGB surgery-induced weight loss (22.9±4.0kg) significantly improved
insulin-stimulated glucose disposal with the greatest change occurring at GDR50, and no
change at GDR100. While the glucose disposal profile still remained insulin resistant relative to
lean volunteers, the improvement was clinically meaningful as it was accompanied by normali-
sation of fasting plasma glucose and HbA1c, and cessation of diabetes medication in all four of
the volunteers with diabetes (Table 2).
Previous studies that have examined the effect of bariatric surgery on IR have used either a
measure of basal insulin sensitivity, HOMA, or a HEC at a single insulin infusion rate equiva-
lent to 1mU/kg /min. In these studies, HOMA and glucose disposal improved significantly
[35–38]. The improvement we see at 1mU/kg/min is of similar magnitude to that reported in
other studies [37], however our study is the first to undertake a detailed examination across a
range of plasma insulin concentrations.
Glucose disposal in the obese subjects after surgery remained highly insulin resistant when
compared with the lean subjects despite significant weight loss, improved glycaemic control
and metabolic parameters. In contrast, surgery-induced weight loss improved Akt-Thr308
phosphorylation (pre vs post surgery, P = 0.020; MANCOVA F-test), and the phosphorylation
of the downstream Akt substrate PRAS40 on Thr246 (P = 0.003, MANCOVA F-test), such that
they became indistinguishable across the insulin dose response profile to those observed in
lean subjects (P = 0.6 and 0.46, respectively; MANCOVA F-test). In human biopsy samples
and human platelets we have previously shown that Thr308 is an excellent biomarker for Akt
kinase activity, which is consistent with this observation [30, 31]. Taken together, this suggests
that the reduced insulin-stimulated Akt-Thr308 phosphorylation, and activity of this kinase to-
wards downstream substrates such as PRAS40, as observed in obese patients before surgery
when compared to lean subjects (P = 0.06 and P = 0.006 for Akt-Thr308 and PRAS40-Thr246,
respectively; MANCOVA F-test), may reflect a state of ‘Akt- resistance’ to insulin action in the
obese, a reversible phenomenon that can be improved by surgery induced weight loss.
We also saw an improvement in insulin-stimulated Akt-Ser473 phosphorylation after sur-
gery in obese subjects (pre vs post surgery, P = 0.027; MANCOVA F-test). However, the reduc-
tion in insulin-stimulated Akt-Ser473 phosphorylation in obese subjects before surgery, when
compared to lean individuals, was not as obvious as it was for Thr308 phosphorylation and
would require a larger sample size to confirm that it normalises in the same manner as Akt-
Thr308 phosphorylation after weight loss.
These data suggest that weight loss can lead to an improvement in insulin signalling, which
is accompanied by a small but clinically significant improvement in GDR. Therefore, any inter-
vention designed to improve insulin signalling in obesity-induced IR could enhance glucose
disposal in a clinically meaningful manner. The data further suggest that a major molecular de-
fect in glucose disposal downstream from Akt signalling, or parallel to it, remains after surgery.
The expression of the insulin responsive glucose transporter GLUT4 in muscle has been re-
ported not to change after gastric bypass surgery [36]. Alternative explanations for this remain-
ing defect in glucose disposal could, therefore arise from: (i) a mis-localisation of GLUT4 in the
cells as previously proposed by Garvey et al [39], (ii) an inability of Akt and/or its substrates to
couple to the GLUT4 translocation machinery, or (iii) a defect in a parallel Akt-independent
signalling pathway such as the Cbl-CAP-C3G pathway [40] or Munc18c tyrosine phosphoryla-
tion [41]. The contribution of these mechanisms to the continuing insulin resistance observed
requires further detailed investigation.
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The mechanism by which weight loss leads to the substantial improvement in Akt-Thr308
and Akt activity leading to PRAS40-Thr246 phosphorylation is unknown. Circulating FFA lev-
els were higher in the obese subjects prior to surgery when compared to lean individuals (759
±86 μmol/L versus 561±80.8 μmol/L, respectively; P = 0.06, unpaired student t-test). Elevated
FFA have been reported to reduce insulin-stimulated IRS1 tyrosine phosphorylation, possibly
via activation of PKCθ, which would be expected to reduce insulin-stimulated Akt activation
[42]. This does not appear to play a role in the current study as no change in circulating FFA
were observed in the obese subjects after surgery (Table 2), although we cannot exclude the
possibility that intramyocellular levels of FFA were reduced after surgery so reducing local
PKCθ activity.
RYGB surgery increases GLP-1 production immediately after the operation and remains el-
evated for at least 18 months [43, 44]. Studies have shown that GLP-1 activates Akt signalling,
either via transactivation of the epidermal growth factor receptor or induction of cAMP and
cAMP response element-binding dependent transcription of IRS2 [45]. Thus the increase in
GLP-1 could be one way that bypass surgery improves insulin signaling. This may partially ex-
plain the normalisation of Akt activity after RYGB, however, there is no direct evidence linking
increased GLP-1 production and improved phosphorylation of Akt in the morbidly obese indi-
viduals undergoing bariatric surgery.
In previous studies, two hour insulin infusion rates were employed before biopsies were
taken as it was considered that this time interval was required before insulin concentrations
and glucose disposal become stable [46]. However Defronzo’s original hyperinsulinaemic
study showed that insulin concentration reach a steady state after 20 minutes [33] and Middel-
beek et al have shown that Akt Thr308 and AS160 phosphorylation was similar in biopsies
taken at 30 minutes and 180 minutes into a hyperinsulinaemic clamp study in lean and obese
patients with and without diabetes [34]. In light of this we elected to do our muscle biopsies
after only 45minutes of insulin infusion. In addition looking at changes with a shorter insulin
infusion time is more physiological as high insulin concentrations are rarely elevated for 2
hours in vivo. It may well be that if we had biopsied after 2hours of insulin we may have seen
slightly different levels of phosphorylation of AKT [47].
It remains to be established whether the glucose disposal profile of our obese volunteers
would approach that of lean individuals upon further weight reduction, as this might be
expected to reduce circulating FFA levels to normal [48, 49]. The findings that only
40–50% of patients with diabetes see a remission in diabetes after RYGB, and of those
10% see a reoccurrence each year despite an improvement in insulin secretion and insulin
receptor concentration, suggest that this does not occur. However in 30 RYGB patients
we have seen further improvements in IR between 6 and 18 months with only 5% more
weight loss [50].
To conclude, our data suggest that an improvement in Akt-Thr308 phosphorylation and its
kinase activity induced by weight loss brought about by bariatric surgery is associated with a
small but clinically significant improvement in glucose homeostasis. However a major defect in
glucose disposal, most likely in muscle, still remains, which underlies IR in morbid obesity and
which is downstream or parallel to Akt signalling. This defect may be overcome once further
weight loss has been attained and circulating FFA levels are normalised, or may remain and
explain why resolution of diabetes after bariatric surgery is not seen in all cases and is not
always permanent.
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